



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/525,044	08/01/2005	Giorgio Mari	P70417US0	5665
136 7590 05/15/2009 JACOBSON HOLMAN PLLC 400 SEVENTH STREET N.W. SUITE 600 WASHINGTON, DC 20004				
EXAMINER				
CHRISTIAN, MARJORIE ELLEN				
ART UNIT		PAPER NUMBER		
1797				
MAIL DATE		DELIVERY MODE		
05/15/2009		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/525,044

**Applicant(s)**

MARI ET AL.

**Examiner**

MARJORIE CHRISTIAN

**Art Unit**

1797

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 13 March 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1 and 3-21 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1 and 3-21 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/CDC)
- 4) ☐ Interview Summary (PTO-413)
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_
- Paper No(s)/Mail Date \_\_\_\_\_

## DETAILED ACTION

### *Response to Amendment*

1. The amendment filed 3/13/2009 has been entered and fully considered.
2. The rejections under 35 USC § 112 are withdrawn in light of Applicant's amendments.
3. Claims 1, 3-21 are pending and have been fully considered.

### *Claim Rejections - 35 USC § 102/103*

4. Claims 1, 3, 7-13, 16-18, 20-21 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over WO00/54873, BORMANN et al. (hereinafter BORMANN) as further evidenced by EP 0 542 655, MAJUREL (hereinafter MAJUREL).


As to Claims 1, 20-21, BORMANN discloses a filter device for the depletion of the leukocyte content from blood products (Abstract) comprising a housing (Fig. 1-2, Ref. 100) with an inlet (20) and an outlet (30) port and, within said housing, more than two porous elements (Pg. 16, Lines 25-28, Fig. 2-3, Ref. 1, 2) adapted for removing leukocytes, each porous element comprising multiple layers of filtering material (Pg. 11, Lines 13-14, Claim 18), wherein the more than two porous elements have a different hydrophilicity (Pg. 12, Lines 5-15), wherein the first porous element has a different hydrophilicity than the successive filter elements, and it is implicit that the difference is a first porous element (closer to inlet) has a higher hydrophilicity than the successive filter elements in the

Art Unit: 1797

direction of flow, from inlet to outlet (Page 12, Lines 6-9, Pg. 11, Lines 15-28, Figs. 1-3).

Alternatively, BORMANN does not appear to expressly disclose that the first porous element has higher hydrophilicity than the successive filter elements. However, it is well known by a person having ordinary skill in the art to the increase the hydrophobicity of the membranes from inlet to outlet in a leukocyte depletion filter to increase efficiency, as evidenced by MAJUREL. MAJUREL discloses a filtration device with different layers having increasing hydrophobicity from inlet to outlet, the increasing hydrophobicity of the layers improves the separation of blood components (Abstract). Further, it has been generally recognized that to shift location of parts when the operation of the device is not otherwise changed is within the level of ordinary skill in the art. *In re Japikse*, 86 USPQ 70; *In re Gazda* 104 USPQ 400.

Further, it would be obvious to one of ordinary skill in the art to use the teachings of these references to arrive at applicant's invention because it produces no more than predictable results. See *KSR Int'l. v. Teleflex Inc.*, 127 S. Ct. 1727, 1732, 82 USPQ2d 1385, 1390 (2007). "it is commonsense that familiar items have obvious uses beyond their primary purposes, and a person of ordinary skill often will be able to fit the teachings of multiple patents together like pieces of a puzzle". "The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results". Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.



As to Claim 3, BORMANN discloses each porous element comprises at least two adjacent layers of filtering material (Pg. 11, Lines 12-14).

As to Claim 7, BORMANN discloses said porous elements are made of fibers consisting of polyolefin (Pg. 11, Line 3) coated with a hydrophilic polymer (Pg. 11, Lines 16-22).

As to Claim 8, BORMANN discloses said hydrophilic polymer is acrylic polymers (Pg. 14, Lines 13-19).

As to Claim 9, BORMANN discloses a filter device including porous elements made of polybutylene terephthalate (Pg 11, Lines 1-5), where first porous element can be coated with a hydrophilic polymer and the second element can be uncoated (Pg. 11, Lines 15-28).

As to Claim 10, BORMANN discloses the porous elements are arranged in the filter device according to a decreasing value of the CWST (Pg. 12, Lines 2-5), from inlet to outlet (Pg. 12, Lines 10-15, Figs. 1-3).

As to Claims 11-12, BORMANN discloses the difference between the hydrophilicity of the inlet (1) and outlet porous element (2), as measured by the CWST of the material is from 10dyn/cm to 20dyn/cm (Pg. 12, Lines 10-15).

As to Claim 13, BORMANN discloses the first porous element has hydrophilicity, as measured by the CWST, of greater than 63dyn/cm (Pg. 12, Lines 6-9).

As to Claim 16, BORMANN discloses a blood bag device for the separation of blood into leukocyte depleted blood components (Fig. 4) comprising a first bag (51), in fluid flow communication with a second bag (50) through a leukocyte filter device (100) according to claim 1 (see 102(b) rejection of Claim 1).

As to Claim 17, BORMANN discloses a method for leukocyte depletion of blood products comprising feeding said blood product through a filter device (BORMANN, Claim 29) according to claim 1 (see 102(b) rejection of Claim 1).

As to Claim 18, BORMANN discloses said blood product is plasma (BORMANN, Claim 9).

#### ***Claim Rejections - 35 USC § 103***

5. **Claims 4-5 are rejected under 35 U.S.C. 103(a) as obvious over WO00/54873, BORMANN et al. (hereinafter BORMANN) in view of US Patent No. 4,925,572, PALL (hereinafter PALL).**

As to Claim 4, BORMANN discloses layers of filtering material in the porous element (Pg. 11, Lines 12-14). BORMANN does not appear to explicitly

Art Unit: 1797

disclose that the layers are made of the same material and subsequently have the same hydrophilicity properties. However, PALL discloses the use of multiple layers in a filter element made of the same material and the material inherently has the same hydrophilicity properties, absent evidence to the contrary (C28/L7-14).

At the time of the invention, it would have been obvious to one of ordinary skill in the art to modify the filter material of the layers of BORMANN to include layers of the same material of PALL. The motivation would have been to efficiently remove micro-aggregates and partially free the fluid from leukocytes (C15/L60-63). Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

As to Claim 5, BORMANN discloses that the filter elements can have different and varied pore structures (Pg. 16, Lines 4-5). Specifically, PALL discloses layers having a decreasing pore size from inlet to outlet (C15/L55-59).

6. **Claim 6 is rejected under 35 USC 103 (a) as being obvious over WO00/54873, BORMANN et al. (hereinafter BORMANN) in view of US Patent No. 5,298,165, OKA et al. (hereinafter OKA).**

As to Claim 6, BORMANN discloses that the filter elements can have different and varied pore structures (Pg. 16, Lines 4-5). BORMANN does not appear to explicitly disclose that the filter elements have decreasing pore size from inlet to outlet. However, OKA discloses two layers have a decreasing pore

Art Unit: 1797

size from inlet to outlet, where the filtering material has a pore size higher than its successive porous element (OKA, Claims 1-2).

At the time of the invention, it would have been obvious to one of ordinary skill in the art to modify the different pore structures of the filter elements of BORMANN to include the decreasing pore size from inlet to outlet of the porous elements of OKA. The motivation would have been to more effectively remove leukocytes from a blood product (Abstract). Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

7. **Claims 14-15, 19 are rejected under 35 USC 103 (a) as being obvious over WO00/54873, BORMANN et al. (hereinafter BORMANN) in view of US Patent No. 5,190,657, HEAGLE et al. (hereinafter HEAGLE).**


As to Claims 14, 19, BORMANN discloses the filter device and filtration elements for leukocyte depletion as shown in the 102(b) rejection of Claim 1. BORMANN does not appear to explicitly disclose the use of a filtration element which is not adapted for leukocyte removal. However, HEAGLE discloses a pre-filter (Fig. 6, Ref. 15) which is not adapted for leukocyte removal and instead remove of agglomerates, the pre-filter is made from woven, non-woven textile materials or metal meshes [*microaggregate filtration elements*] (C14/L9-16).

At the time of the invention, it would have been obvious to one of ordinary skill in the art to modify the filtration device for leukocyte depletion of BORMANN to include the pre-filter element which is not adapted for leukocyte removal of



Art Unit: 1797

HEAGLE. The suggestion would have been to remove large agglomerates prior to contact with the filter element (C14/L9-16). Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.



As to Claim 15, HEAGLE discloses said filter elements not adapted for leukocyte removal (15) are located closer to the inlet (18) than said elements adapted for leukocyte removal (1).

### ***Response to Arguments***

8. Applicant's arguments filed 3/13/2009 have been fully considered but they are not persuasive in view of the new grounds of rejection necessitated by amendment.

### ***Conclusion***

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

- US Patent No. 4,880,548 as it discloses a CWST of the filter element of 90dyn/cm;
- US Patent No. 4,985,153 as it discloses layers of filter material for leukocyte depletion; and
- US Patent No. 5,229,012 discloses as it discloses a CWST between 10-20dyn/cm for a leukocyte depletion filter.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARJORIE CHRISTIAN whose telephone /number is (571)270-5544. The examiner can normally be reached on Monday through Thursday 7-5pm (Fridays off).

Art Unit: 1797

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vickie Kim can be reached on (571)272-0579. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MC

/Krishnan S Menon/  
Primary Examiner, Art Unit 1797